Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622
Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all T...
Gespeichert in:
| Veröffentlicht in: | PloS one 2013-05, Vol.8 (5) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | |
| container_title | PloS one |
| container_volume | 8 |
| creator | Ali, Alima Hassen Belachew, Tefera Yami, Alemeshet Ayen, Wubeante Yenet |
| description | Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all TB/HIV co-infected patients who commenced anti-TB treatment from January 2008 to December 2011 at Jimma University Hospital. Patients who had developed hepatotoxicity after at least 5 days of standard doses of anti-TB drug therapy were labeled as "cases" and those without hepatotoxicity were "controls". Each case with anti-TB drug induced hepatotoxicity was compared with 3 controls selected randomly from the cohort. From a cohort of 296 TB/HIV co-infected patients 8 were excluded from the study as the causality between anti-TB drugs and hepatotoxicity was not confirmed, 33 had developed hepatotoxicity. On bivariate logistic regression analysis, body mass index (BMI) |
| doi_str_mv | 10.1371/journal.pone.0064622 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1399908119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1399908119</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_13999081193</originalsourceid><addsrcrecordid>eNqVj01OwzAQRi0kJMrPDVjMkgVJ7QRCww5CUcoCIRHYViaZFleOJ3hsRI_CbUkRF2D1bd6T3ifEqZKpyq_UdEPRO23TgRymUhYXRZbtiYkq8ywpMpkfiEPmjZSX-awoJuL7xgWTNPENfRstsWG483ENC9fFFjuocdCBAn2Z1oQt6J7cGprbab14hYqShVthG0buSQeDLjDoAA-m7zW8OPOJnndWTTyYoO05zMO7ocHoa3hE3nmVZkwqcsGThecQu20K-Bt9LPZX2jKe_O2ROLufN1WdDJ4-4mgve8MtWqsdUuSlysuylDM1Pv0H-gOUE2OG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399908119</pqid></control><display><type>article</type><title>Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ali, Alima Hassen ; Belachew, Tefera ; Yami, Alemeshet ; Ayen, Wubeante Yenet</creator><creatorcontrib>Ali, Alima Hassen ; Belachew, Tefera ; Yami, Alemeshet ; Ayen, Wubeante Yenet</creatorcontrib><description>Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all TB/HIV co-infected patients who commenced anti-TB treatment from January 2008 to December 2011 at Jimma University Hospital. Patients who had developed hepatotoxicity after at least 5 days of standard doses of anti-TB drug therapy were labeled as "cases" and those without hepatotoxicity were "controls". Each case with anti-TB drug induced hepatotoxicity was compared with 3 controls selected randomly from the cohort. From a cohort of 296 TB/HIV co-infected patients 8 were excluded from the study as the causality between anti-TB drugs and hepatotoxicity was not confirmed, 33 had developed hepatotoxicity. On bivariate logistic regression analysis, body mass index (BMI) <18.5 Kg/m2 [P = 0.01; OR (95%CI): 3.6 (1.4-9.5)], disseminated pulmonary TB [P = 0.00; OR (95%CI): 5.6 (2.2-14.6)], CD4 count less than or equal to 50 [P = 0.016; OR (95%CI): 3.6(1.27-10.23)] and WHO stage 4 [P = 0.004, OR (95%CI): 3.8 (1.68-8.77)] were significantly associated with anti-TB drug induced hepatotoxicity. Predictor variables with p-value <0.05 by bivariate analysis were analyzed using multivariable logistic regression analysis and identified disseminated pulmonary TB [P = 0.001; AOR (95%CI) = 5.6 (2.1-15.0)] and BMI <18.5 [P = 0.014; AOR (95%CI) = 3.6 (1.3-10.1)] as independent predictors of anti-TB drug induced hepatotoxicity. Conclusions The incidence of anti-TB drug induced hepatotoxicity was 11.5%. The results suggest that in the presence of disseminated pulmonary TB and/or BMI <18.5 Kg/m2, TB/HIV co-infected patients should be closely followed for the occurrence of hepatotoxicity during the intensive phase of TB treatment to prevent morbidity and mortality.</description><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0064622</identifier><language>eng</language><subject>Body mass index ; Human immunodeficiency virus</subject><ispartof>PloS one, 2013-05, Vol.8 (5)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Ali, Alima Hassen</creatorcontrib><creatorcontrib>Belachew, Tefera</creatorcontrib><creatorcontrib>Yami, Alemeshet</creatorcontrib><creatorcontrib>Ayen, Wubeante Yenet</creatorcontrib><title>Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622</title><title>PloS one</title><description>Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all TB/HIV co-infected patients who commenced anti-TB treatment from January 2008 to December 2011 at Jimma University Hospital. Patients who had developed hepatotoxicity after at least 5 days of standard doses of anti-TB drug therapy were labeled as "cases" and those without hepatotoxicity were "controls". Each case with anti-TB drug induced hepatotoxicity was compared with 3 controls selected randomly from the cohort. From a cohort of 296 TB/HIV co-infected patients 8 were excluded from the study as the causality between anti-TB drugs and hepatotoxicity was not confirmed, 33 had developed hepatotoxicity. On bivariate logistic regression analysis, body mass index (BMI) <18.5 Kg/m2 [P = 0.01; OR (95%CI): 3.6 (1.4-9.5)], disseminated pulmonary TB [P = 0.00; OR (95%CI): 5.6 (2.2-14.6)], CD4 count less than or equal to 50 [P = 0.016; OR (95%CI): 3.6(1.27-10.23)] and WHO stage 4 [P = 0.004, OR (95%CI): 3.8 (1.68-8.77)] were significantly associated with anti-TB drug induced hepatotoxicity. Predictor variables with p-value <0.05 by bivariate analysis were analyzed using multivariable logistic regression analysis and identified disseminated pulmonary TB [P = 0.001; AOR (95%CI) = 5.6 (2.1-15.0)] and BMI <18.5 [P = 0.014; AOR (95%CI) = 3.6 (1.3-10.1)] as independent predictors of anti-TB drug induced hepatotoxicity. Conclusions The incidence of anti-TB drug induced hepatotoxicity was 11.5%. The results suggest that in the presence of disseminated pulmonary TB and/or BMI <18.5 Kg/m2, TB/HIV co-infected patients should be closely followed for the occurrence of hepatotoxicity during the intensive phase of TB treatment to prevent morbidity and mortality.</description><subject>Body mass index</subject><subject>Human immunodeficiency virus</subject><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqVj01OwzAQRi0kJMrPDVjMkgVJ7QRCww5CUcoCIRHYViaZFleOJ3hsRI_CbUkRF2D1bd6T3ifEqZKpyq_UdEPRO23TgRymUhYXRZbtiYkq8ywpMpkfiEPmjZSX-awoJuL7xgWTNPENfRstsWG483ENC9fFFjuocdCBAn2Z1oQt6J7cGprbab14hYqShVthG0buSQeDLjDoAA-m7zW8OPOJnndWTTyYoO05zMO7ocHoa3hE3nmVZkwqcsGThecQu20K-Bt9LPZX2jKe_O2ROLufN1WdDJ4-4mgve8MtWqsdUuSlysuylDM1Pv0H-gOUE2OG</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Ali, Alima Hassen</creator><creator>Belachew, Tefera</creator><creator>Yami, Alemeshet</creator><creator>Ayen, Wubeante Yenet</creator><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20130501</creationdate><title>Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622</title><author>Ali, Alima Hassen ; Belachew, Tefera ; Yami, Alemeshet ; Ayen, Wubeante Yenet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_13999081193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Body mass index</topic><topic>Human immunodeficiency virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ali, Alima Hassen</creatorcontrib><creatorcontrib>Belachew, Tefera</creatorcontrib><creatorcontrib>Yami, Alemeshet</creatorcontrib><creatorcontrib>Ayen, Wubeante Yenet</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ali, Alima Hassen</au><au>Belachew, Tefera</au><au>Yami, Alemeshet</au><au>Ayen, Wubeante Yenet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622</atitle><jtitle>PloS one</jtitle><date>2013-05-01</date><risdate>2013</risdate><volume>8</volume><issue>5</issue><eissn>1932-6203</eissn><abstract>Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all TB/HIV co-infected patients who commenced anti-TB treatment from January 2008 to December 2011 at Jimma University Hospital. Patients who had developed hepatotoxicity after at least 5 days of standard doses of anti-TB drug therapy were labeled as "cases" and those without hepatotoxicity were "controls". Each case with anti-TB drug induced hepatotoxicity was compared with 3 controls selected randomly from the cohort. From a cohort of 296 TB/HIV co-infected patients 8 were excluded from the study as the causality between anti-TB drugs and hepatotoxicity was not confirmed, 33 had developed hepatotoxicity. On bivariate logistic regression analysis, body mass index (BMI) <18.5 Kg/m2 [P = 0.01; OR (95%CI): 3.6 (1.4-9.5)], disseminated pulmonary TB [P = 0.00; OR (95%CI): 5.6 (2.2-14.6)], CD4 count less than or equal to 50 [P = 0.016; OR (95%CI): 3.6(1.27-10.23)] and WHO stage 4 [P = 0.004, OR (95%CI): 3.8 (1.68-8.77)] were significantly associated with anti-TB drug induced hepatotoxicity. Predictor variables with p-value <0.05 by bivariate analysis were analyzed using multivariable logistic regression analysis and identified disseminated pulmonary TB [P = 0.001; AOR (95%CI) = 5.6 (2.1-15.0)] and BMI <18.5 [P = 0.014; AOR (95%CI) = 3.6 (1.3-10.1)] as independent predictors of anti-TB drug induced hepatotoxicity. Conclusions The incidence of anti-TB drug induced hepatotoxicity was 11.5%. The results suggest that in the presence of disseminated pulmonary TB and/or BMI <18.5 Kg/m2, TB/HIV co-infected patients should be closely followed for the occurrence of hepatotoxicity during the intensive phase of TB treatment to prevent morbidity and mortality.</abstract><doi>10.1371/journal.pone.0064622</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1932-6203 |
| ispartof | PloS one, 2013-05, Vol.8 (5) |
| issn | 1932-6203 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1399908119 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS) Journals Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Body mass index Human immunodeficiency virus |
| title | Anti-Tuberculosis Drug Induced Hepatotoxicity among TB/HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study. e64622 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Tuberculosis%20Drug%20Induced%20Hepatotoxicity%20among%20TB/HIV%20Co-Infected%20Patients%20at%20Jimma%20University%20Hospital,%20Ethiopia:%20Nested%20Case-Control%20Study.%20e64622&rft.jtitle=PloS%20one&rft.au=Ali,%20Alima%20Hassen&rft.date=2013-05-01&rft.volume=8&rft.issue=5&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0064622&rft_dat=%3Cproquest%3E1399908119%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1399908119&rft_id=info:pmid/&rfr_iscdi=true |